First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. - Wikidata - wikimedia - TriplyDB

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

http://www.wikidata.org/entity/Q48476437

about

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results Treatment of advanced squamous cell carcinoma of the lung: a review Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Medical management of lung cancer: Experience in China Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer Irreversible EGFR-TKIs: dreaming perfection Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Review of the current targeted therapies for non-small-cell lung cancer Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review Targeted therapies in development for non-small cell lung cancer Tailored therapy in lung cancer Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer Mechanisms of resistance to EGFR-targeted drugs: lung cancer Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.

P2860

3b3f867141955f01fbf3cdad7bc45de5df28371f 4ec29d69a1163695a1cc2b6a506a06d612d37670

P248

Q21132047-0B3A8734-3F33-435D-B78E-71E3A2FF3322 Q21132357-4ED8D2F6-6FC1-492A-A12D-ED744AB95EEE Q24201207-E316E30C-9E73-4215-B2AA-40ECBB6402F8 Q24564024-DF780D93-7A1A-446F-9516-77A93A4E958B Q26471909-170DA15A-35D3-4A57-A45D-F1641A8A330A Q26744339-2E0606BD-3227-4642-AFED-D998E2A36F05 Q26745427-98BA6B5C-8CD8-4A84-93BF-B34A62EBDE7C Q26768125-E697E44A-5C38-4BE7-AD86-8EF058AA5212 Q26774897-CA4C8F03-5121-454E-91F0-956F96111AD7 Q26775392-04B6FB40-F476-4BCD-AF97-0B15119089FA Q26786580-CF492156-ECD7-4A70-998F-AABA9AE45388 Q26786932-C5005453-0A47-440A-871E-DAA4B4479AD8 Q26797297-69D5C2FC-5081-4BB5-9953-98DBCF6C2E02 Q26798257-1F1F188E-589B-4F68-B8DA-B1271E20D219 Q26799390-06DE0454-57A4-4C01-AA9D-4645AF7E8A6B Q26799467-8472ED8D-F1C9-4C57-9B18-FBC7A3BDA590 Q26824315-7D4FDBB3-60D0-4FC6-8EAA-AF81811564CB Q26828860-84782475-0AC6-4514-8851-B0A8D796A03B Q26852507-50F0192E-5E59-4A1E-919E-816165C38DE3 Q26866186-BBB54712-6AC9-46AF-84FF-4711C94E15CC Q27011355-F7117978-7FBD-472F-8640-49142A1ED325 Q27014117-030A6CA1-5E49-458C-8B9B-21AF69D24041 Q27015079-D94358F0-92FD-47A9-8E9E-F2EBABD7E845 Q27021203-AF8D49AB-5CC7-48DF-805D-21B3D5795651 Q27022535-4B0DB828-DEE3-4235-9CA2-AB2897349D51 Q27022852-A4BB66F6-E4F7-48BA-8FC9-E81903BCDEF4 Q27026316-F304D07F-E110-45B3-8ABC-AF8710B44EDC Q27027957-70DAE60F-BC08-4A8F-B836-CACC463B4E3C Q27853221-723D9F65-8936-4812-B461-7EDFE1BAFB8E Q28068930-C7081BE5-E126-419E-8471-A5A2798EB4ED Q28071772-58A3583D-5172-424F-A54C-465D0A5DE469 Q28073920-5EF75539-855E-4CD0-AE29-259BB56B508A Q28075704-13C95560-D739-4608-B9C2-815E0E36CA89 Q28077415-D70DBEC9-016C-4922-A2A6-4CAC6B9393CD Q28082499-E67973EF-4703-47B8-B336-134EDF5B87E6 Q28382921-C5A2FA4B-ACBD-46F1-B2B9-3FC5B87ACAA4 Q28387151-FC084680-0E5F-4EE1-9407-9F2E59462B40 Q28943366-847BAFA1-6FDC-40C4-8B40-3CABA39F98BD Q30239901-55B9C559-E554-4CF3-A3D7-7C648049F393 Q30248499-D01D2004-7C5F-477C-8667-BAC98ACC1C19

P2860

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

http://www.wikidata.org/entity/Q48476437

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@en

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@nl

type

label

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@en

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@nl

prefLabel

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@en

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@nl

P1433

Q48476437-3152E140-4F0B-4584-B08C-4F6E5580B12A

P1476

Q48476437-B885B1EF-0C2D-4C03-B081-089228CC74D1

P2093

Q48476437-15412E5A-AE6C-4066-81D3-BAB07ABB1CA2

Q48476437-1667A5B0-55BE-45F0-A7A6-3274CFF8BEDF

Q48476437-2004D5E6-7939-49E1-AA00-55EB81F5C8CD

Q48476437-2E527C95-CBE4-405D-B23A-CEBEDFE9A71A

Q48476437-486522C7-7CCB-404A-87CB-9819E7562001

Q48476437-530C78DD-ED3D-4473-9559-B1C0B80009CF

Q48476437-73ECDCA3-6A9C-4EC2-8932-7C07297EF56F

Q48476437-77BDE7C3-5244-40D6-A911-3B2F38B09231

Q48476437-B51D9547-74B7-4C7F-9176-4F51E3D71C3A

Q48476437-C28CCEC1-A1F3-4A05-8649-1761E4D518EF

P304

Q48476437-78B628B5-77EA-4397-9C72-CCE32203D9B9

P31

Q48476437-270BEA41-8551-4FAA-9881-066ACBC3DF98

P356

Q48476437-65F6F84F-4956-4515-8871-C0EAB855DA00

P407

Q48476437-B379A32A-2256-4744-9CBA-059DFDA42E4E

P433

Q48476437-BF6DD40A-B7F3-405F-B530-BF2C5CFAC770

P478

Q48476437-DC4E01B5-499A-49F1-AD29-BCE62F9D7657

P577

Q48476437-B7453710-F0A3-46A4-83F4-9FCA22626185

P698

Q48476437-9AA6E7B6-2D52-4093-8836-B771E3E79389

P921

Q48476437-D047BBBF-D36C-4E60-B245-F6B3310BCF51

P356

JCO.2011.36.8456

P1433

Journal of Clinical Oncology

P1476

First-SIGNAL: first-line singl ...... th adenocarcinoma of the lung.

@en

P2093

Cheolwon Suh

http://www.w3.org/2001/XMLSchema#string

Dae Ho Lee

http://www.w3.org/2001/XMLSchema#string

Heung Tae Kim

http://www.w3.org/2001/XMLSchema#string

Hyae Young Kim

http://www.w3.org/2001/XMLSchema#string

Jae Won Lee

http://www.w3.org/2001/XMLSchema#string

Ji-Youn Han

http://www.w3.org/2001/XMLSchema#string

Jin Seok Ahn

http://www.w3.org/2001/XMLSchema#string

Jin Soo Lee

http://www.w3.org/2001/XMLSchema#string

Jong Hee Han

http://www.w3.org/2001/XMLSchema#string

Jung-Shin Lee

http://www.w3.org/2001/XMLSchema#string

P304

1122-1128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.36.8456

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22370314

http://www.w3.org/2001/XMLSchema#string

P921